Longevity investment bulletin: CohBar, Heartseed, Juvenescence and more

Longevity investment bulletin: Cerevance, Frequency, Heartseed, Life Biosciences and more

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The latest longevity updates from our investment news desk.

CohBar to merge with Morphogenesis

Clinical stage biotech CohBar (NASDAQ: CWBR) and Morphogenesis announced a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2098

Celularity

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 8: Systemic aging reversal
    Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

Celularity is a clinical and commercial-stage regenerative medicine company specializing in off-the-shelf allogeneic cell therapies derived from postpartum placental tissue. The company develops multiple therapeutic platforms including mesenchymal-like adherent stromal cells (MLASCs), natural killer (NK) cells, engineered T cells with CAR modifications, and exosome-based therapies, alongside a portfolio of advanced biomaterial products. Celularity's therapeutic focus spans age-related diseases, cancer, infectious diseases, and degenerative conditions, with the overarching mission of addressing fundamental aging mechanisms including cellular senescence, chronic inflammation, and tissue degeneration.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE